Iovance Biotherapeutics, Inc. Common Stock
IOVAIovance Biotherapeutics, Inc. (IOVA) is a biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. It specializes in T-cell therapy platforms aimed at harnessing the body's immune system to target and destroy cancer cells. The company’s primary focus is on personalized, off-the-shelf T-cell therapies for various solid tumors and hematologic malignancies.
Company News
Iovance Biotherapeutics announced the grant of inducement stock options covering 139,930 shares to seventeen new non-executive employees on July 16, 2026, with an exercise price of $4.66 per share and a three-year vesting schedule. The grants were made under the company's Amended and Restated 2021 Inducement Plan in compliance with Nasdaq Listing...
The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and strong profitability, against Iovance Biotherapeutics, an emerging biotech firm with innovative cancer therapies showing 60.6% revenue growth but still unprofitable. The author recommends Amgen for 2026 due to its stability, dividend, and proven track recor...
Iovance Biotherapeutics approved the grant of inducement stock options covering 140,860 shares to 27 new non-executive employees on June 18, 2026, with an exercise price of $3.91 per share. The options vest over three years under the company's Amended and Restated 2021 Inducement Plan.
Iovance Biotherapeutics approved the grant of inducement stock options covering 93,340 shares to thirteen new non-executive employees on May 21, 2026, with an exercise price of $3.70 per share and a three-year vesting schedule.
Iovance Biotherapeutics (IOVA) has surged 34% in 2026 but lost 90% over five years. Wall Street analysts project a 165% upside to $9, driven by strong revenue growth (61% YoY) from its melanoma drug Amtagvi and potential expansion into lung cancer. However, the analyst remains skeptical, citing manufacturing complexity, high costs, and regulatory...
